Market Place
Sourcing Support
Palisade Bio to Present at Needham Healthcare Conference
08 Apr 2026 //
GLOBENEWSWIRE
Palisade Bio Unveils Positive Phase 1B Data For PALI-2108
30 Mar 2026 //
GLOBENEWSWIRE
Palisade Bio Presents PALI-2108 Data At ECCO 2026
23 Feb 2026 //
GLOBENEWSWIRE
Palisade Bio Joins Piper Sandler Immunology Symposium
09 Feb 2026 //
GLOBENEWSWIRE
Palisade Bio To Present At Oppenheimer Healthcare Conference
05 Feb 2026 //
GLOBENEWSWIRE
Palisade Bio To Present Two Abstracts At Top IBD Conferences
16 Jan 2026 //
GLOBENEWSWIRE
Palisade Bio Secures Investment From Crohn`s & Colitis
07 Jan 2026 //
GLOBENEWSWIRE
Palisade Bio To Present At Piper Sandler Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Palisade Bio Names Sharon Skare as VP, Global Clinical Operations
28 Oct 2025 //
GLOBENEWSWIRE
Palisade Bio Initiates Phase 1B Study Of PALI-2108,
20 Oct 2025 //
GLOBENEWSWIRE
Palisade Bio Secures Canadian Patent For PALI-2108 Composition
13 Oct 2025 //
GLOBENEWSWIRE
Palisade Bio Prices Upsized $120m Public Stock Offering
01 Oct 2025 //
GLOBENEWSWIRE
Palisade Bio Reports Positive PALI-2108 Ph 1b Clinical Data
17 Sep 2025 //
GLOBENEWSWIRE
Palisade Bio Gets Health Canada Nod for PALI-2108 Ph 1b Trial
05 Sep 2025 //
GLOBENEWSWIRE
Palisade Bio Launche Virtual Investor Connect on FSCD & PALI-2108
25 Aug 2025 //
GLOBENEWSWIRE
Palisade Bio Shows 100% Response in Ph 1b Ulcerative Colitis
07 Aug 2025 //
GLOBENEWSWIRE
Palisade Gets Patent Approval for PALI-2108 Composition in China
31 Jul 2025 //
GLOBENEWSWIRE
Palisade Bio Shows PALI-2108 Potential for Ulcerative Colitis & IBS
06 May 2025 //
GLOBENEWSWIRE
Palisade Bio Finishes Phase 1a Dosing of PALI-2108 Study
09 Apr 2025 //
GLOBENEWSWIRE
Palisade Bio Starts Dosing in First UC Patient Cohort in PALI-210
14 Mar 2025 //
GLOBENEWSWIRE
Palisade Bio Gets SR&ED Funds For PALI-2108 In Ulcerative Colitis
20 Feb 2025 //
GLOBENEWSWIRE
Palisade Bio Joins Virtual Investor “Top 5 for ‘25” Conference
19 Feb 2025 //
GLOBENEWSWIRE
Palisade Bio Presents Preclinical Data for Ulcerative Colitis
10 Feb 2025 //
GLOBENEWSWIRE
Palisade Bio Advance Ph 1 Study Of PALI-2108 For Ulcerative Colitis
16 Jan 2025 //
GLOBENEWSWIRE
Palisade Bio Presents PALI-2108 Preclinical Results for Crohn’s & UC
21 Nov 2024 //
GLOBENEWSWIRE
Palisade Bio Doses First Subject in PALI-2108 UC Phase 1 Study
07 Nov 2024 //
GLOBENEWSWIRE
Palisade Bio Reports Positive Ulcerative Colitis Data for PALI-2108
31 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio Cleared For PALI-2108 Phase 1 In Ulcerative Colitis
10 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio Launches New Branding And Reiterates Commitment
16 Sep 2024 //
GLOBENEWSWIRE
Palisade Bio bolsters branding with bold new logo, website makeover
16 Sep 2024 //
FIERCE PHARMA
Palisade Bio Reports Data On PDE4B Expression In Patients Cohorts
05 Sep 2024 //
GLOBENEWSWIRE
Palisade Bio Announces NOA for Canadian Patent Covering Lead Product , PALI-2108
11 Jun 2024 //
GLOBENEWSWIRE
Palisade`s PALI-2108 Shows Bioactivation, Efficacy In Mouse Models
21 May 2024 //
GLOBENEWSWIRE
Palisade Bio, Strand Partner On Precision Medicine
23 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Demonstrates PALI-2108 Bioactivation in Ulcerative Colitis Study
16 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Presents Development Overview of PALI-2108
10 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108
29 Jan 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Receipt of Second Milestone Payment for PALI-2108
28 Dec 2023 //
GLOBENEWSWIRE
